相关实验视频

Updated: Jun 5, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

独特的结构配置的EV-DNA原始库弗弗细胞介导的抗瘤免疫力,以防止转移性进展

Inbal Wortzel¹, Yura Seo², Ife Akano³

¹Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

|December 3, 2024

概括

携带独特修饰的DNA (EV-DNA) 的细胞外囊 (EVs) 通过在免疫细胞中引发DNA损伤反应来激活抗瘤免疫力. 这一发现揭示了EV-DNA作为结直肠癌转移的潜在生物标志物.

科学领域:

细胞生物学细胞生物学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

细胞外囊泡 (EVs) 对于细胞间通信至关重要,它们携带着各种生物分子.
以前的研究表明,EVs含有基因组DNA (EV-DNA),但包装机制和癌症作用尚不清楚.

研究的目的:

为了阐明EV-DNA的包装机制.
研究EV-DNA在癌症进展和免疫反应中的作用.
确定EV-DNA作为结直肠癌转移的潜在生物标志物.

主要方法:

全基因组的CRISPR淘汰查,以确定调节EV-DNA包装的基因.
分析EV-DNA局部化和基因组修饰的分析.
使用结直肠癌模型进行体内研究,以评估Kupffer细胞 (KCs) 中的EV-DNA吸收和免疫反应.

主要成果:

EV-DNA主要位于EV的表面,与修饰和分裂的基因组有关.
免疫发育途径,包括APAF1和NCF1,调节EV-DNA包装.
基因细胞对EV-DNA的摄取诱导了DNA损伤反应,改变了细胞因子的产生,促进了三级淋巴体结构,并抑制了肝转移.
丢失APAF1损害了EV-DNA包装,并增加了肝脏转移.
结肠直肠癌活检EV-DNA分泌预测了手术后的转移.

结论:

独特的染色化EV-DNA包装是由特定的免疫基因调节的.
凯基细胞吸收EV-DNA会触发抗瘤免疫,抑制转移.
EV-DNA分泌是一种有希望的结直肠癌转移的预测生物标志物.

更多相关视频

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...